Literature DB >> 25736312

Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

Athena Kritharis1, Michael Coyle1, Jaya Sharma1, Andrew M Evens1.   

Abstract

Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration-approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in several additional lymphoma subtypes. There are many ongoing clinical trials examining the use of lenalidomide alone or in combinatorial therapy. It will be important in these studies to delineate reliable, predictive biomarkers to optimally integrate lenalidomide into lymphoma treatment paradigms.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25736312      PMCID： PMC4467884          DOI： 10.1182/blood-2014-11-567792

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  49 in total

1.  Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.

Authors:  Francisco J Hernandez-Ilizaliturri; Nishitha Reddy; Beata Holkova; Edris Ottman; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

3.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

4.  Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Authors:  Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman
Journal:  Br J Haematol       Date:  2007-11-09       Impact factor: 6.998

5.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

6.  lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Authors:  Lei Wu; Mary Adams; Troy Carter; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

7.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Authors:  Peter H Wiernik; Izidore S Lossos; Joseph M Tuscano; Glen Justice; Julie M Vose; Craig E Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Thomas M Habermann
Journal:  J Clin Oncol       Date:  2008-07-07       Impact factor: 44.544

8.  Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Thomas M Habermann; Izidore S Lossos; Glen Justice; Julie M Vose; Peter H Wiernik; Kyle McBride; Kenton Wride; Annette Ervin-Haynes; Kenichi Takeshita; Dennis Pietronigro; Jerome B Zeldis; Joseph M Tuscano
Journal:  Br J Haematol       Date:  2009-02-24       Impact factor: 6.998

9.  Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.

Authors:  Dan Zhu; Laura G Corral; Yuedi W Fleming; Bernd Stein
Journal:  Cancer Immunol Immunother       Date:  2008-04-08       Impact factor: 6.968

10.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

Authors:  Alan G Ramsay; Amy J Johnson; Abigail M Lee; Güllü Gorgün; Rifca Le Dieu; William Blum; John C Byrd; John G Gribben
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808
View more
  25 in total

Review 1.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

2.  TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

Review 3.  The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

Authors:  Trent Peng Wang; John Harwood Scott; Stefan Klaus Barta
Journal:  Ther Adv Hematol       Date:  2017-11-22

4.  Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.

Authors:  Pooja Sabhachandani; Saheli Sarkar; Seamus Mckenney; Dashnamoorthy Ravi; Andrew M Evens; Tania Konry
Journal:  J Control Release       Date:  2018-12-12       Impact factor: 9.776

5.  Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.

Authors:  Adrian Tempescul; Jean-Christophe Ianotto; Cristina Bagacean; Pierre-Yves Salaun; Corina Bocsan; Mihnea Zdrenghea
Journal:  Int J Hematol       Date:  2016-05-27       Impact factor: 2.490

Review 6.  Pitfalls of Combining Novel Agents in Lymphoma.

Authors:  Thomas D Rodgers; Paul M Barr
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 7.  Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

Authors:  Neha Mehta-Shah; Nancy L Bartlett
Journal:  Blood       Date:  2018-03-02       Impact factor: 22.113

8.  Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Authors:  François Lemonnier; Violaine Safar; Asma Beldi-Ferchiou; Anne-Ségolène Cottereau; Emmanuel Bachy; Guillaume Cartron; Virginie Fataccioli; Laura Pelletier; Cyrielle Robe; Audrey Letourneau; Edoardo Missiaglia; Slim Fourati; Marie-Pierre Moles-Moreau; Alain Delmer; Reda Bouabdallah; Laurent Voillat; Stéphanie Becker; Céline Bossard; Marie Parrens; Olivier Casasnovas; Victoria Cacheux; Caroline Régny; Vincent Camus; Marie-Hélène Delfau-Larue; Michel Meignan; Laurence de Leval; Philippe Gaulard; Corinne Haioun
Journal:  Blood Adv       Date:  2021-01-26

Review 9.  Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.

Authors:  Jeffrey D Cooney; Ricardo C T Aguiar
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

Review 10.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma.

Authors:  Nikki Blosser; Jennifer Jupp; Patrick Yau; Douglas Stewart
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.